Edison Investment Research - SU PLC (SUS) SU - The time to look ahead

Report

Edison Investment Research

Pedro Fonseca

S&U - The time to look ahead

In line with earlier guidance, S&U reported H125 PBT of £12.8m, a significant decline versus H124 but an improvement versus H224. Customer repayment collections and earnings in the motor finance business were materially affected by the temporary restrictions agreed with the Financial Conduct Authority (FCA). These have since been lifted, and while regulatory discussions are ongoing, this is an important step towards the strong recovery in motor finance earnings that we forecast. Meanwhile, as previously reported, the property lending division continues to perform strongly, with a positive outlook for continuing growth.

15/10/2024 1 EN

Underlying

S&U PLC

S & U is engaged in the provision of consumer credit and car finance throughout the United Kingdom.

See profile

GB0007655037 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

Edison Investment Research

S&U - Timing is everything

Interim results, for the six months to 31 July (H125), will be published on 8 October. Ahead of that, S&U has alerted the market that based on the H1 performance, full year PBT is unlikely to meet the previous market consensus expectations. We believe this to be primarily a timing issue, reflecting the continuing impact of the temporary FCA restrictions on collections activity in the motor finance business. Once regulatory clarity has been established, we expect a significant recovery. Meanwhile, as previously reported, the property lending division continues to perform strongly. We have reduc...

September 23, 2024 September 23, 2024 1 EN

Edison Investment Research

S&U - Anticipating regulatory clarity in H2

S&U’s H1 trading statement revealed similar trends to those in Q1. Advantage Finance remains in a consolidation phase amid industry discussions with the FCA on collections procedures and forbearance. The collection rate slipped slightly from 88% in Q1 to 87% for the half year. In contrast, Aspen Bridging continues to grow healthily with receivables up 13% since year-end, ‘excellent’ credit quality and a strong pipeline. Significantly, S&U describes the negotiations with the FCA as ‘nearing their conclusion’, which suggests there is potential for recovery at Advantage in H2. The latest 25bp bas...

August 12, 2024 August 12, 2024 1 EN

Actinogen Medical - A$11.1m capital raise completed

Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its previously disclosed A$8.1m share placement, total funds from the combined capital raising reached the targeted A$11.1m in gross proceeds. The company expects that the total proceeds will enable its operating runway to reach the release of top-line results for its XanaMIA Phase IIb/III trial in patients with mild-to-moderate Alzheimer’s disease (AD), expected in mid-CY26. The next major catalyst for Actinogen is the interim results on the first c 100 patient...

1h / 50m 1h / 50m 1 EN

Martyn King

Martyn King

Calgro M3 - Earnings underpinned by gross profit margin

Calgro M3’s core business is integrated residential housing development and memorial parks. In the six months to August 2024, the company posted a 28.5% increase in EPS to 101.4 cents, which also represented a three-year EPS compound annual growth rate (CAGR) of 37%. This was supported by a strong gross profit margin of 29.7%, a 383% increase in the share of profits from joint ventures and a 2% decrease in admin costs. Group revenue declined by 26.4% to ZAR507m, compared to H123, but the gross profit margin, which exceeded the target range of 20–25%, offset the decline in revenue. The net asse...

2h / 15m 2h / 15m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

S&U - The time to look ahead

S&U - Timing is everything

S&U - Anticipating regulatory clarity in H2

Actinogen Medical - A$11.1m capital raise completed

Calgro M3 - Earnings underpinned by gross profit margin

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe